JP2023525981A5 - - Google Patents

Info

Publication number
JP2023525981A5
JP2023525981A5 JP2022566063A JP2022566063A JP2023525981A5 JP 2023525981 A5 JP2023525981 A5 JP 2023525981A5 JP 2022566063 A JP2022566063 A JP 2022566063A JP 2022566063 A JP2022566063 A JP 2022566063A JP 2023525981 A5 JP2023525981 A5 JP 2023525981A5
Authority
JP
Japan
Prior art keywords
lung
dione
item
pharmaceutically acceptable
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/053651 external-priority patent/WO2021220250A1/en
Publication of JP2023525981A publication Critical patent/JP2023525981A/ja
Publication of JP2023525981A5 publication Critical patent/JP2023525981A5/ja
Pending legal-status Critical Current

Links

JP2022566063A 2020-04-30 2021-04-30 肺炎症および間質性肺疾患を処置するためのレリグリタゾン Pending JP2023525981A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382356 2020-04-30
EP20382356.2 2020-04-30
PCT/IB2021/053651 WO2021220250A1 (en) 2020-04-30 2021-04-30 Leriglitazone for treating lung inflammation and interstitial lung disease

Publications (2)

Publication Number Publication Date
JP2023525981A JP2023525981A (ja) 2023-06-20
JP2023525981A5 true JP2023525981A5 (cg-RX-API-DMAC7.html) 2024-05-10

Family

ID=70779625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566063A Pending JP2023525981A (ja) 2020-04-30 2021-04-30 肺炎症および間質性肺疾患を処置するためのレリグリタゾン

Country Status (11)

Country Link
US (1) US20230172921A1 (cg-RX-API-DMAC7.html)
EP (1) EP4142720A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525981A (cg-RX-API-DMAC7.html)
KR (1) KR20230035522A (cg-RX-API-DMAC7.html)
CN (1) CN116390725A (cg-RX-API-DMAC7.html)
AU (1) AU2021265345A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021951A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180351A1 (cg-RX-API-DMAC7.html)
IL (1) IL297771A (cg-RX-API-DMAC7.html)
MX (1) MX2022013021A (cg-RX-API-DMAC7.html)
WO (1) WO2021220250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
JP2026500743A (ja) * 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ.エレ. レリグリタゾンの最適投薬
WO2024231881A2 (en) * 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222272B1 (en) * 2008-08-07 2012-11-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US20120190637A1 (en) * 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2011073662A1 (en) * 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MX379710B (es) * 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
MX2020013182A (es) * 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.

Similar Documents

Publication Publication Date Title
JP2024170583A5 (cg-RX-API-DMAC7.html)
JP2023522010A5 (cg-RX-API-DMAC7.html)
JP2004525903A5 (cg-RX-API-DMAC7.html)
EP3240538B1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
JP2008538115A5 (cg-RX-API-DMAC7.html)
JP2009507909A5 (cg-RX-API-DMAC7.html)
JP2005504804A5 (cg-RX-API-DMAC7.html)
AU2015292256B2 (en) Treatment and prevention of the common cold using povidone-iodine
JP2023510332A5 (cg-RX-API-DMAC7.html)
JP5470245B2 (ja) バイオフィルム形成の処置のためのトリアゾール化合物
JP2010527960A5 (cg-RX-API-DMAC7.html)
JP2002528502A5 (cg-RX-API-DMAC7.html)
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
CN111867582A (zh) 衣壳组装调节剂给药方案
JPWO2023054732A5 (cg-RX-API-DMAC7.html)
JP2024164177A (ja) 疣贅の治療
JP2001072585A (ja) ウイルス性心筋炎の予防または治療薬剤
ATE398441T1 (de) Octenidinhaltige lutschtabletten gegen entzündliche erkrankungen des mund- und rachenraums
JP2005513014A5 (cg-RX-API-DMAC7.html)
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2013510838A (ja) 微生物感染症の治療
JP2005524666A5 (cg-RX-API-DMAC7.html)
JP2002523458A5 (cg-RX-API-DMAC7.html)
Schack et al. Endocarditis caused by Actinobacillus actinomycetemcomitans
CN115607545B (zh) 依达拉奉在自闭症谱系障碍治疗中的应用